JP2011510076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510076A5 JP2011510076A5 JP2010544340A JP2010544340A JP2011510076A5 JP 2011510076 A5 JP2011510076 A5 JP 2011510076A5 JP 2010544340 A JP2010544340 A JP 2010544340A JP 2010544340 A JP2010544340 A JP 2010544340A JP 2011510076 A5 JP2011510076 A5 JP 2011510076A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- modified polypeptide
- polypeptide according
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 49
- 229920001184 polypeptide Polymers 0.000 claims description 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 10
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 8
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 239000004215 Carbon black (E152) Substances 0.000 claims description 6
- 229930195733 hydrocarbon Natural products 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000711950 Filoviridae Species 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 108010072476 SIV envelope protein gp41 Proteins 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- CYNVQWNFIFUJRX-ICEZVUAISA-N chembl427630 Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CYNVQWNFIFUJRX-ICEZVUAISA-N 0.000 claims 1
- 238000002983 circular dichroism Methods 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 16
- 108090000317 Chymotrypsin Proteins 0.000 description 4
- 102000057297 Pepsin A Human genes 0.000 description 4
- 108090000284 Pepsin A Proteins 0.000 description 4
- 229960002376 chymotrypsin Drugs 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6200708P | 2008-01-23 | 2008-01-23 | |
| US61/062,007 | 2008-01-23 | ||
| PCT/US2009/000438 WO2009108261A2 (en) | 2008-01-23 | 2009-01-23 | Compositions and methods for the treatment of viral infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510076A JP2011510076A (ja) | 2011-03-31 |
| JP2011510076A5 true JP2011510076A5 (https=) | 2012-03-08 |
| JP5788178B2 JP5788178B2 (ja) | 2015-09-30 |
Family
ID=41016644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010544340A Expired - Fee Related JP5788178B2 (ja) | 2008-01-23 | 2009-01-23 | ウィルス感染症の治療のための組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9290545B2 (https=) |
| EP (1) | EP2247606B1 (https=) |
| JP (1) | JP5788178B2 (https=) |
| CA (1) | CA2713089C (https=) |
| WO (1) | WO2009108261A2 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2822302A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Methods of impairing osteoclast differentiation |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| AU2007307254A1 (en) * | 2006-10-05 | 2008-04-17 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| US8937154B2 (en) | 2006-10-05 | 2015-01-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| WO2009110952A2 (en) | 2007-12-31 | 2009-09-11 | New York University | Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices |
| JP5788178B2 (ja) | 2008-01-23 | 2015-09-30 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | ウィルス感染症の治療のための組成物及び方法 |
| CA2725227A1 (en) | 2008-05-06 | 2009-11-12 | Asim Kumar Debnath | Antiviral cell penetrating peptides |
| ES2666458T3 (es) | 2008-09-22 | 2018-05-04 | Aileron Therapeutics, Inc. | Macrociclos peptidomiméticos |
| EP2352507A4 (en) | 2008-11-24 | 2012-04-25 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES |
| US9079970B2 (en) | 2008-12-09 | 2015-07-14 | Dana Farber Cancer Institute, Inc. | Methods and compositions for specific modulation of MCL-1 |
| WO2010083347A2 (en) | 2009-01-14 | 2010-07-22 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| CA2761568C (en) * | 2009-06-18 | 2020-10-13 | Dana-Farber Cancer Institute, Inc. | Structured viral peptide compositions and methods of use |
| GB2471692A (en) * | 2009-07-08 | 2011-01-12 | Complix Nv | HIV gp41-binding single-chain coiled-coil peptide comprising heptad repeats |
| JP2014502152A (ja) | 2010-11-12 | 2014-01-30 | ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド | 癌の治療及び診断 |
| US9029332B2 (en) | 2010-12-15 | 2015-05-12 | The Research Foundation For The State University Of New York | Cross-linked peptides and proteins, methods of making same, and uses thereof |
| WO2012142604A2 (en) | 2011-04-15 | 2012-10-18 | Dana-Farber Cancer Institute, Inc. | Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9 |
| CA2862391C (en) * | 2011-12-29 | 2023-10-10 | Loren D. Walensky | Stabilized antiviral fusion helices |
| BR112014022958A2 (pt) * | 2012-03-20 | 2017-07-18 | Merck Sharp & Dohme | peptídeo mimético de gp41, composição imunogênica, e, método para obter uma resposta imune em um hospedeiro mamífero |
| CN103483428B (zh) * | 2012-06-11 | 2017-05-17 | 中国人民解放军军事医学科学院毒物药物研究所 | 抑制hiv感染的小分子‑多肽缀合物 |
| US9493562B2 (en) | 2012-07-19 | 2016-11-15 | Alethia Biotherapeutics Inc. | Anti-Siglec-15 antibodies |
| US10106590B2 (en) | 2013-03-15 | 2018-10-23 | Dana-Farber Cancer Institute, Inc. | BH4 stabilized peptides and uses thereof |
| AU2014227824B2 (en) | 2013-03-15 | 2018-09-27 | Dana-Farber Cancer Institute, Inc. | Stabilized SOS1 peptides |
| US10308926B2 (en) | 2013-03-15 | 2019-06-04 | Dana-Farber Cancer Institute, Inc. | Stablized EZH2 peptides |
| US9644002B2 (en) | 2013-07-25 | 2017-05-09 | Yale University | Allosteric modulators of EGFR and constitutively active mutants |
| US10172961B2 (en) | 2014-05-07 | 2019-01-08 | Cornell University | Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them |
| US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| WO2017004591A2 (en) | 2015-07-02 | 2017-01-05 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides |
| WO2017018595A1 (ko) * | 2015-07-28 | 2017-02-02 | 동국대학교 산학협력단 | 이중 스테이플화된 펩타이드 및 이의 용도 |
| EP3341008B1 (en) | 2015-08-28 | 2026-04-15 | Dana-Farber Cancer Institute, Inc. | Peptides binding to bfl-1 |
| WO2017040323A2 (en) | 2015-08-28 | 2017-03-09 | Dana-Farber Cancer Institute, Inc. | Stabilized peptides for covalent binding to target protein |
| JP7105696B2 (ja) | 2016-02-29 | 2022-07-25 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド |
| JP7069126B2 (ja) | 2016-08-26 | 2022-05-17 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 化学療法誘発性末梢性ニューロパシーおよび難聴を処置または予防するためのｂｃｌ－ｗポリペプチドおよび模倣物 |
| EP3551213A4 (en) | 2016-12-07 | 2020-11-04 | The University of Chicago | FOX3 INHIBITION COMPOSITIONS AND METHODS |
| JP7305614B2 (ja) | 2017-07-19 | 2023-07-10 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド |
| EA202090513A1 (ru) | 2017-09-07 | 2020-08-24 | Фог Фармасьютикалз, Инк. | Агенты, модулирующие функции бета-катенина, и связанные способы |
| WO2019090015A1 (en) | 2017-11-03 | 2019-05-09 | Yale University | Peptidic materials that traffic efficiently to the cell cytosol and nucleus |
| CA3079758A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides |
| CN108822190B (zh) * | 2018-05-23 | 2021-11-09 | 中国人民解放军军事科学院军事医学研究院 | 多肽及其药物组合物和用途 |
| EP3840766A4 (en) | 2018-08-20 | 2022-06-22 | Fog Pharmaceuticals, Inc. | Collections of peptides, peptide agents, and methods of use thereof |
| CA3173973A1 (en) * | 2020-03-04 | 2021-09-10 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized sars-cov-2 peptides and uses thereof |
| WO2021183463A1 (en) * | 2020-03-09 | 2021-09-16 | President And Fellows Of Harvard College | Compositions and methods for treating coronavirus |
| WO2021207517A2 (en) * | 2020-04-10 | 2021-10-14 | Sapience Therapeutics, Inc. | Modified hr2 peptide inhibitors of coronavirus fusion |
| AU2021258205A1 (en) * | 2020-04-22 | 2022-10-13 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ACE2 helix 1 peptides and uses thereof |
| AU2021360898A1 (en) * | 2020-10-14 | 2023-03-23 | Dana-Farber Cancer Institute, Inc. | Chimeric conjugates for degradation of viral and host proteins and methods of use |
| US20240226304A1 (en) * | 2020-10-14 | 2024-07-11 | The Trustees Of Columbia University In The City Of New York | Lipopeptide fusion inhibitors as sars-cov-2 antivirals |
| US11479582B2 (en) | 2020-10-16 | 2022-10-25 | King Faisal University | Anti-SARS-CoV-2 fusion peptides |
| WO2022098848A1 (en) * | 2020-11-05 | 2022-05-12 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ebolavirus peptides and uses thereof |
| US20240052330A1 (en) * | 2020-12-22 | 2024-02-15 | The University Of Chicago | Blockade of sars-cov-2 infection using hydrocarbon stapled peptides |
| EP4453245A4 (en) * | 2021-12-23 | 2025-12-31 | Mammoth Biosciences Inc | DOSING IMPROVEMENTS BASED ON A PROGRAMMABLE NUCLEASE |
| WO2026024936A2 (en) | 2024-07-25 | 2026-01-29 | Dana-Farber Cancer Institute, Inc. | Bh4 domain peptides and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0938497B1 (en) | 1996-11-06 | 2007-02-28 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| US6271198B1 (en) | 1996-11-06 | 2001-08-07 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| JP2003529319A (ja) * | 1999-01-08 | 2003-10-07 | キャロル ディ． ウエイス， | ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法 |
| US20060241027A1 (en) * | 2002-02-07 | 2006-10-26 | Hans-Peter Hauser | Hiv inhibiting proteins |
| WO2005034842A2 (en) * | 2003-05-19 | 2005-04-21 | Progenics Pharmaceuticals, Inc. | Peptides useful as hiv fusion inhibitors |
| EP1997828B1 (en) * | 2003-11-05 | 2017-10-04 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides from BCL-2 and uses thereof |
| BRPI0418304A (pt) | 2004-01-07 | 2007-05-02 | Trimeris Inc | peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv |
| WO2006121809A2 (en) * | 2005-05-06 | 2006-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibition of membrane fusion proteins |
| JP5783721B2 (ja) * | 2007-09-26 | 2015-09-24 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｂｃｌ−２ファミリーポリペプチドを調節する方法及び組成物 |
| EP2205256A4 (en) | 2007-09-26 | 2012-10-24 | Dana Farber Cancer Inst Inc | REAGENTS TO TRIGGER IMMUNE REACTION |
| JP5788178B2 (ja) | 2008-01-23 | 2015-09-30 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | ウィルス感染症の治療のための組成物及び方法 |
-
2009
- 2009-01-23 JP JP2010544340A patent/JP5788178B2/ja not_active Expired - Fee Related
- 2009-01-23 EP EP09715505.5A patent/EP2247606B1/en active Active
- 2009-01-23 CA CA2713089A patent/CA2713089C/en not_active Expired - Fee Related
- 2009-01-23 WO PCT/US2009/000438 patent/WO2009108261A2/en not_active Ceased
-
2010
- 2010-07-23 US US12/864,375 patent/US9290545B2/en not_active Expired - Fee Related
-
2016
- 2016-02-09 US US15/019,558 patent/US20160152667A1/en not_active Abandoned
- 2016-05-04 US US15/146,511 patent/US10259848B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011510076A5 (https=) | ||
| JP4925540B2 (ja) | ５−ヘリックスタンパク質 | |
| JP5788178B2 (ja) | ウィルス感染症の治療のための組成物及び方法 | |
| Root et al. | HIV-1 gp41 as a target for viral entry inhibition | |
| Ellis Dutch et al. | Virus membrane fusion proteins: biological machines that undergo a metamorphosis | |
| Weissenhorn et al. | Structural basis for membrane fusion by enveloped viruses | |
| Schibli et al. | Class I and class II viral fusion protein structures reveal similar principles in membrane fusion | |
| DE60311731T2 (de) | Verfahren zur rekombinanten Herstellung von Antifusogenikpeptide | |
| JP2002503477A5 (https=) | ||
| JP2012509340A5 (https=) | ||
| Igonet et al. | SnapShot: Viral and eukaryotic protein fusogens | |
| Luo | The nucleocapsid of vesicular stomatitis virus | |
| CA2450548C (en) | Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments | |
| Pérot et al. | From viruses to genes: syncytins | |
| AU2005225063B2 (en) | Peptide inhibitors of HIV entry | |
| Poumbourios et al. | Evolutionary conservation of the membrane fusion machine | |
| AU2001292944A1 (en) | Peptide inhibitors of HIV entry | |
| Gao | Peptide inhibitors targeting virus-cell fusion in class I enveloped viruses | |
| Kingsman et al. | Retroelement particles as purification, presentation and targeting vehicles | |
| CN101724027A (zh) | 蛋白质三聚体化模序及其应用 | |
| Quinlan et al. | An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines | |
| Bianchi et al. | Covalent Trimeric Coiled Coils of the HIV gp41 HR1 Region are Extremely Potent and Broadly Neutralizing Inhibitors of Viral Infection | |
| Dieckmann et al. | Structure and Dynamics in Viral RNA Packaging | |
| WO2003006056A2 (en) | End-locked five-helix protein |